Sabin inactivated polio vaccine - Beijing Minhai Biotechnology
Alternative Names: sIPV - Beijing Minhai BiotechnologyLatest Information Update: 08 Jan 2025
At a glance
- Originator Beijing Minhai Biotechnology
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Poliomyelitis
Most Recent Events
- 08 Mar 2023 Beijing Minhai Biotechnology initiates phase-II clinical trials in Poliomyelitis (In infants, Prevention) in China (IM) (NCT06752174)